La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Monopar Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Monopar Therapeutics..

Monopar Therapeutics (NASDAQ:MNPR) Azioni, Catena delle Opzioni

MONOPAR THERAPEUTICS INC

Monopar Therapeutics

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Monopar Therapeutics Inc

Health Care

Press Releases

Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025

Earnings

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

General

Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

News

Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting

Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting

Monopar Announces Journal of Hepatology Publishes Physicians' Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients

Financing

Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting® 2025

MNPR

Absci

ADC Therapeutics

Akebia Therapeutics

Bicycle Therapeutics plc - American Depositary Shares

Bicycle Therapeutics

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Emergent BioSolutions

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Gossamer Bio

Inventiva S.A. - American Depository Shares

Inventiva

Jade Biosciences

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharmaceuticals

Keros Therapeutics

NovaBridge Biosciences - American Depositary Shares

NovaBridge Biosciences

Neurogene

Ocugen

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Organogenesis Holdings

Prothena Corporation plc - Ordinary Shares

Prothena Corp

PureTech Health plc - American Depositary Shares

PureTech Health

Regenxbio

Rigel Pharmaceuticals, Inc. - Common Stock

Comments

Monopar Therapeutics

Monopar Therapeutics (MNPR) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO